Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind comparison of SOK583A1 versus Eylea in wet age-related macular degeneration
MOH_2021-02-08_009714Phase 3Recruiting
- Sponsor
- Hexal AG
- Start
- Jan 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of 9MW0813 and aflibercept in exudative macular degeneration (2 arms), sponsored by Hexal AG. Started Jan 2021; status: recruiting.
02
Drugs
9MW0813aflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on MOH_2021-02-08_009714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-02-08_009714.